Therapeutic Potential of Umbilical Cord Mesenchymal Stromal Cells Transplantation for Cerebral Palsy: A Case Report

Cell Therapy Center, 323 Hospital of People's Liberation Army, Xi'an 710054, China.
Case reports in transplantation 03/2013; 2013(4):146347. DOI: 10.1155/2013/146347
Source: PubMed


Cerebral palsy is the most common motor disability in childhood. In current paper, we first report our clinical data regarding administration of umbilical cord mesenchymal stem cells (MSCs) transplantation in treatment of cerebral palsy. A 5-year-old girl with cerebral palsy was treated with multiple times of intravenous and intrathecal administration of MSCs derived from her young sister and was followed up for 28 months. The gross motor dysfunction was improved. Other benefits included enhanced immunity, increased physical strength, and adjusted speech and comprehension. Temporary low-grade fever was the only side effect during the treatment. MSCs may be a safe and effective therapy to improve symptoms in children with cerebral palsy.

Download full-text


Available from: Liming Wang, Jan 24, 2015
  • Source
    • "The patient was given 7 transplantations of MSCs over a 6-month period, and was followed for 28 months after the final transplantation. Specifically, the study reported a reduction of ambulation with tumble, with the patient being able to stand up by herself, as well as other improvements such as enhanced immunity, increased physical strength, and adjusted speech and comprehension (Wang et al., 2013a). "
    [Show abstract] [Hide abstract]
    ABSTRACT: In the research, clinical and wider community there is great interest in the use of stem cells to reduce the progression, or indeed repair brain injury. Perinatal brain injury may result from acute or chronic insults sustained during fetal development, during the process of birth, or in the newborn period. The most readily identifiable outcome of perinatal brain injury is cerebral palsy, however this is just one consequence in a spectrum of mild to severe neurological deficits. As we review, there are now clinical trials taking place worldwide targeting cerebral palsy with stem cell therapies. It will likely be many years before strong evidence-based results emerge from these trials. With such trials underway, it is both appropriate and timely to address the physiological basis for the efficacy of stem-like cells in preventing damage to, or regenerating, the newborn brain. Appropriate experimental animal models are best placed to deliver this information. Cell availability, the potential for immunological rejection, ethical and logistical considerations, together with the propensity for native cells to form terratomas, make it unlikely that embryonic or fetal stem cells will be practical. Fortunately, these issues do not pertain to the use of human amnion epithelial cells (hAECs), or umbilical cord blood (UCB) stem cells that are readily and economically obtained from the placenta and umbilical cord discarded at birth. These cells have the potential for transplantation to the newborn where brain injury is diagnosed or even suspected. We will explore the novel characteristics of hAECs and undifferentiated UCB cells, as well as UCB-derived endothelial progenitor cells and mesenchymal stem cells, and how immunomodulation and anti-inflammatory properties are principal mechanisms of action that are common to these cells, and which in turn may ameliorate the cerebral hypoxia and inflammation that are final pathways in the pathogenesis of perinatal brain injury.
    Frontiers in Neuroscience 10/2013; 7(article 194):194. DOI:10.3389/fnins.2013.00194 · 3.66 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: To assess feasibility and safety of providing autologous umbilical cord blood (UCB) cells to neonates with hypoxic-ischemic encephalopathy (HIE). We enrolled infants in the intensive care nursery who were cooled for HIE and had available UCB in an open-label study of non-cyropreserved autologous volume- and red blood cell-reduced UCB cells (up to 4 doses adjusted for volume and red blood cell content, 1-5 × 10(7) cells/dose). We recorded UCB collection and cell infusion characteristics, and pre- and post-infusion vital signs. As exploratory analyses, we compared cell recipients' hospital outcomes (mortality, oral feeds at discharge) and 1-year survival with Bayley Scales of Infant and Toddler Development, 3rd edition scores ≥85 in 3 domains (cognitive, language, and motor development) with cooled infants who did not have available cells. Twenty-three infants were cooled and received cells. Median collection and infusion volumes were 36 and 4.3 mL. Vital signs including oxygen saturation were similar before and after infusions in the first 48 postnatal hours. Cell recipients and concurrent cooled infants had similar hospital outcomes. Thirteen of 18 (74%) cell recipients and 19 of 46 (41%) concurrent cooled infants with known 1-year outcomes survived with scores >85. Collection, preparation, and infusion of fresh autologous UCB cells for use in infants with HIE is feasible. A randomized double-blind study is needed.
    The Journal of pediatrics 12/2013; 164(5). DOI:10.1016/j.jpeds.2013.11.036 · 3.79 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: To compare the efficacy of cord blood mononuclear cells (MNCs) and CD34+ cells for the treatment of neonatal mice models with cerebral palsy (CP). CP model in neonatal mice was established by the ligation of carotid artery. Mice were randomly designated into MNCs group, CD34+ group, model group and control group (30 mice per group). MNCs and CD34+ cells were isolated from human umbilical cord blood. MNCs were transplanted into mice in the MNCs group and CD34+ cells into mice in the CD34+ group through the jugular vein, respectively. The body weight, histopathology, apoptosis-related gene expression, learning and memory, and motor function of mice in the four groups were compared. Compared with control group, the body weight of mice in model group was significantly lower (P
    Cell Biochemistry and Biophysics 09/2014; 70(3). DOI:10.1007/s12013-014-0090-6 · 1.68 Impact Factor
Show more